KR950016724A - 폐경기 후 여성의 리비도를 증가시키는 방법 - Google Patents

폐경기 후 여성의 리비도를 증가시키는 방법 Download PDF

Info

Publication number
KR950016724A
KR950016724A KR1019940034915A KR19940034915A KR950016724A KR 950016724 A KR950016724 A KR 950016724A KR 1019940034915 A KR1019940034915 A KR 1019940034915A KR 19940034915 A KR19940034915 A KR 19940034915A KR 950016724 A KR950016724 A KR 950016724A
Authority
KR
South Korea
Prior art keywords
compound
women
formula
menopause
chem
Prior art date
Application number
KR1019940034915A
Other languages
English (en)
Inventor
조셉 세일즈 제임스
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016724A publication Critical patent/KR950016724A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 폐경기 후의 여성의 리비도 증가를 필요로하는 여성에게 효과량의 하기 일반식(I)의 화합물 또는 약학적으로 허용가능한 그의 염 또는 용매화물을 투여함을 포함하는 폐경기 후의 여성의 리비도를 증가시키는 방법에 관한 것이다.
상기식에서,
R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

폐경기 후 여성의 리비도를 증가시키는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 폐경기 후 여성의 리비도를 증가시키는데 사용하기 위한 하기 일반식(Ⅰ)의 화합물 또는 약학적으로 허용가능한 그의 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  2. 제1항에 있어서, 상기 화합물이 염산 염인 화합물.
  3. 제1항에 있어서, 예방적인 목적으로 투여되는 화합물.
  4. 제1항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034915A 1993-12-21 1994-12-19 폐경기 후 여성의 리비도를 증가시키는 방법 KR950016724A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,329 1993-12-21
US08/171,329 US5439931A (en) 1993-12-21 1993-12-21 Method for increasing libido in post-menopausal women

Publications (1)

Publication Number Publication Date
KR950016724A true KR950016724A (ko) 1995-07-20

Family

ID=22623352

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034915A KR950016724A (ko) 1993-12-21 1994-12-19 폐경기 후 여성의 리비도를 증가시키는 방법

Country Status (21)

Country Link
US (1) US5439931A (ko)
EP (1) EP0659411B1 (ko)
JP (1) JPH07215865A (ko)
KR (1) KR950016724A (ko)
CN (1) CN1107705A (ko)
AT (1) ATE203405T1 (ko)
AU (1) AU690595B2 (ko)
CA (1) CA2138497A1 (ko)
CZ (1) CZ320594A3 (ko)
DE (1) DE69427806T2 (ko)
DK (1) DK0659411T3 (ko)
ES (1) ES2157960T3 (ko)
GR (1) GR3036983T3 (ko)
HU (1) HUT71477A (ko)
IL (1) IL112035A (ko)
NO (1) NO944925L (ko)
NZ (1) NZ270163A (ko)
PT (1) PT659411E (ko)
RU (1) RU94044321A (ko)
SI (1) SI0659411T1 (ko)
ZA (1) ZA9410094B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
WO1996012489A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2003070253A1 (en) * 2002-02-21 2003-08-28 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
CA2138497A1 (en) 1995-06-22
AU8154194A (en) 1995-06-29
IL112035A (en) 1999-03-12
SI0659411T1 (en) 2001-12-31
HU9403661D0 (en) 1995-02-28
IL112035A0 (en) 1995-03-15
ES2157960T3 (es) 2001-09-01
HUT71477A (en) 1995-11-28
RU94044321A (ru) 1996-10-20
GR3036983T3 (en) 2002-01-31
EP0659411B1 (en) 2001-07-25
CN1107705A (zh) 1995-09-06
NO944925D0 (no) 1994-12-19
DE69427806T2 (de) 2001-12-06
PT659411E (pt) 2001-11-30
US5439931A (en) 1995-08-08
ATE203405T1 (de) 2001-08-15
CZ320594A3 (en) 1995-09-13
EP0659411A3 (en) 1995-09-27
DE69427806D1 (de) 2001-08-30
JPH07215865A (ja) 1995-08-15
ZA9410094B (en) 1996-06-19
NO944925L (no) 1995-06-22
AU690595B2 (en) 1998-04-30
EP0659411A2 (en) 1995-06-28
NZ270163A (en) 1996-08-27
DK0659411T3 (da) 2001-09-24

Similar Documents

Publication Publication Date Title
KR950010893A (ko) 자궁내막증 억제 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016744A (ko) 트롬빈을 저해하는 방법
RU97108050A (ru) Способ ингибирования состояний, связанных с нейропептидом y
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR970705384A (ko) 골 보철 파손의 억제 방법(methods for inhibiting bone prosthesis degeneration)
KR950016729A (ko) 유방 질환의 억제 방법
KR950016733A (ko) 난소 발육부전, 사춘기 지연, 또는 성적 유치증의 억제방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application